Annexon, Inc. (ANNX)

 Annexon Inc (ANNX) is a clinical-stage biopharmaceutical company focused on developing treatments for patients with classical complement-mediated disorders of the body's immune system. The company's pipeline includes several candidates targeting C1q, a protein in the complement system that plays a role in the clearance of damaged cells and debris from the body.

ANNX's lead candidate ANX005 is a monoclonal antibody designed to selectively inhibit the classical complement pathway by targeting C1q. ANX005 is being evaluated in clinical trials for the treatment of Guillain-Barre Syndrome (GBS) and warm autoimmune hemolytic anemia (WAIHA). In addition to ANX005, Annexon is also developing ANX007, a C1q inhibitor that is currently in preclinical development for a range of complement-mediated diseases.

Annexon was founded in 2011 and is headquartered in South San Francisco, California.